These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29848153)

  • 1. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department.
    Roche H; Bouiller K; Puzenat E; Deveza E; Roche B; Pelletier F; van de Laak A; Dupond AS; Nardin C; Aubin F
    J Dermatolog Treat; 2019 Sep; 30(6):540-544. PubMed ID: 29848153
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.
    Verma L; Mayba JN; Gooderham MJ; Verma A; Papp KA
    J Cutan Med Surg; 2018; 22(1):38-43. PubMed ID: 29056080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
    Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
    Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics.
    Tokuyama M; Ota M; Saitoh R; Sawamura M; Okitsu N; Shimizu T; Kondoh A; Yamaoka H; Mabuchi T
    Tokai J Exp Clin Med; 2020 Dec; 45(4):230-235. PubMed ID: 33300595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
    Assan F; Tubach F; Arlegui H; Viguier M; Beylot-Barry M; Dupuy A; Beneton N; Joly P; Jullien D; Mahé E; Paul C; Richard MA; Bachelez H; Giboin C; Chosidow O; Sbidian E;
    Dermatology; 2021; 237(3):338-346. PubMed ID: 33535213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of Biologic Therapy in Psoriasis.
    Cardona R; Pelet Del Toro NM; Michelen-Gómez E; Arias-Berrios GE; Martín-García RF
    P R Health Sci J; 2021 Jun; 40(2):63-67. PubMed ID: 34543563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.
    Goren A; Carter C; Lee S
    J Dermatolog Treat; 2016; 27(1):43-50. PubMed ID: 26088404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
    Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
    Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.
    Lin PT; Wang SH; Chi CC
    Sci Rep; 2018 Oct; 8(1):16068. PubMed ID: 30375427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug survival of biologic treatments in Turkish patients with psoriasis.
    Yayli S; Baykal Selcuk L; Aksu Arica D; Bayrak S
    Dermatol Ther; 2020 Nov; 33(6):e13917. PubMed ID: 32594635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
    Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
    JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug survival of biologic treatments in psoriasis: a systematic review.
    No DJ; Inkeles MS; Amin M; Wu JJ
    J Dermatolog Treat; 2018 Aug; 29(5):460-466. PubMed ID: 29076754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
    Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.
    Jacobi A; Rustenbach SJ; Augustin M
    Int J Dermatol; 2016 Mar; 55(3):296-302. PubMed ID: 26470689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.